States’ Statutes Of Limitations Apply To Federal FCA Retaliation Claims
Client Alert | less than 1 min read | 06.27.05
Resolving a split among circuits regarding the proper statute of limitations to apply in "retaliation" claims brought by aggrieved whistleblowers against their employers under the federal civil False Claims Act, the Supreme Court in Graham County Soil & Water Conserv. Dist. v. U.S. ex rel. Wilson (June 20, 2005) held that, instead of the familiar six-year limitations period for substantive FCA allegations, the most analogous statute of limitations under state law (typically, state employment or other tort law) applies. The majority reasoned that, otherwise, the limitations period would be left without a starting point and would be inconsistent with the general rule that Congress drafts statutes of limitations to begin when the plaintiff has a “complete and present cause of action.”
Insights
Client Alert | 4 min read | 04.09.26
DOJ Establishes National Fraud Enforcement Division
On April 7, 2026, Acting Attorney General Todd Blanche issued a memorandum establishing the National Fraud Enforcement Division (NFED) within the U.S. Department of Justice (DOJ). This new division will be dedicated to the centralized, coordinated investigation and prosecution of fraud against taxpayer dollars and taxpayer-funded programs. AAG Blanche acknowledged that, while DOJ has a “storied history of combatting fraud,” DOJ has “never adopted a comprehensive and coordinated approach to investigating and prosecuting fraud against taxpayer dollars and tax-payer funded programs.” The NFED was created to close that gap with its core mission being to “zealously investigate and prosecute those who steal or fraudulently misuse taxpayer dollars.”
Client Alert | 2 min read | 04.09.26
OMB Issues New Policy on Federal IT Transparency and Acquisition Oversight
Client Alert | 5 min read | 04.09.26
U.S. State Privacy Enforcement: Key Priorities and Practical Guidance From State Regulators
Client Alert | 4 min read | 04.08.26
Cosmetics Under the Microscope: FDA’s Expanding Regulatory Reach Under MoCRA
